Clinical Trial Detail

NCT ID NCT02088541
Title Selinexor (KPT-330) in Older Patients With Relapsed AML
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Indications

acute myeloid leukemia

Therapies

Cytarabine

Azacitidine

Decitabine

Selinexor

Hydroxyurea

Age Groups: adult senior

No variant requirements are available.